A limitation of the current study is its focus on tumor-cell-intrinsic MYC, specifically regarding its role downstream of the MEK/MAPK pathway in regulating processes such as cell survival, cell cycle progression, proliferation, DNA damage, and apoptotic cell death, as revealed by MEK inhibition with trametinib. The gene discussed is MAP2K7; the disease is neoplasm.